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Gene delivery systems can be divided to two major types: vector-based (either viral
vector or non-viral vector) and physical delivery technologies. Many physical carriers,
such as electroporation, gene gun, ultrasound start to be proved to have the potential
to enable gene therapy. A relatively new physical delivery technology for gene delivery
consists of microneedles (MNs), which has been studied in many fields and for many
molecule types and indications. Microneedles can penetrate the stratum corneum, which
is the main barrier for drug delivery through the skin with ease of administration and
without significant pain. Many different kinds of MNs, such as metal MNs, coated MNs,
dissolving MNs have turned out to be promising in gene delivery. In this review, we
discussed the potential as well as the challenges of utilizing MNs to deliver nucleic acids
for gene therapy. We also proposed that a combination of MNs and other gene delivery
approaches may lead to a better delivery system for gene therapy.
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INTRODUCTION
Gene therapy is a technique to transport genetic materials to a specific cell with the aim to correct
or compensate for the genetic defects, thereby achieving the goal to treat diseases (Mulligan, 1993).
With the development of molecular biology and biotechnology, we can replace the mutant gene in
the diseased cells to treat genetic diseases, such as hemophilia, muscular dystrophy, cystic fibrosis
(Mulligan, 1993). We can also treat genetic disorders by delivering genetic materials to targeted
cells (Pack et al., 2005). The first gene therapy clinical trial started with the severe combined
immunodeficiency (SCID) in 1990 (Blaese et al., 1995). Cavazzana-Calvo firstly reported the
successful clinical case of gene therapy in April, 2000 (Cavazzana-Calvo et al., 2000). In July 2012,
the EuropeanMedicines Agency recommended the approval of Glybera, which is a gene therapy for
the treatment of lipoprotein lipase deficiency (LPLD) (Bryant et al., 2013; Watanabe et al., 2015).
There have been many clinical trials of gene therapy approved so far, but the success rate
has been low (Kay et al., 2000; Khuri et al., 2000). On the other hand, the discovery of the
phenomenon of RNA interference may open a new road for the gene therapy (Fire et al., 1998).
Compared with the traditional gene therapy, siRNA can efficiently silence the diseased gene and
knock down its function. The sequences of siRNAs can be rationally designed to target specific
genes. The effects of siRNA can be quick and significant. All the recent progresses make gene
therapy enter a new revolution. Recent therapeutic trials of siRNA have been carried out with
macular degeneration, diabetic macular edema, solid tumors, respiratory diseases, syncytial virus,
and human immunodeficiency viral infections, etc. (Novobrantseva et al., 2008; Castanotto and
Rossi, 2009; Whitehead et al., 2009). However, Andrew Z. Fire, the Nobel Prize recipient for
discovering RNA interference, said that the lack of efficient delivery systems of siRNA may be the
next obstacle for gene therapy when he was awarded on the podium in 2006 (Fire, 2007).
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The big challenge now is to find a safe and efficient delivery
system to help genetic materials or siRNAs target to the specific
cell. Microneedles (MNs), as a new transdermal delivery system,
has the potential to greatly enhance the cutaneous delivery of
low, medium, and high molecular weight therapeutic agents
(Coulman et al., 2006). Recently, MNs has also been studied to
deliver genetic materials for gene therapy (Niidome and Huang,
2002; McCaffrey et al., 2015). In this review, some accessible
MNs-based methods for gene delivery with clinical potential will
be reviewed and the future prospects of MNs-based delivery
systems will also be discussed.
THE EXISTING PROBLEMS OF GENE
DELIVERY
In general, the gene delivery systems have been developed into
the following three major types: viral vectors, non-viral vectors,
and physical delivery carriers. The related studies have proved
their effectiveness in delivering genetic materials or siRNAs. But
many critical issues still remained to be solved.
Viral vectors use the natural ability of virus to transport the
genetic materials into infected cells. The construction of viral
vectors retains the necessary components of the genetic material
and knocks down the pathogenic components (McCaffrey et al.,
2016). It has been widely applied in clinical trials of gene
therapy for retrovirus, lenti virus, adeno-associated virus, and
adenovirus, etc (Mountain, 2000; Cots et al., 2013; Kotterman
et al., 2015). However, the gene delivery vectors derived from
viruses have the potential to be pathogenic because of their
potential tumorigenicity and immunogenicity. Moreover, the
potential for vector integration and insertional mutagenesis also
limits the use of viral vectors (Lentz et al., 2012). In addition, the
costly scale-up production, insufficient capacity for cell targeting
and low level of transgene expression remind us to find a more
safe and effective vector for therapeutic gene delivery (Weinberg
et al., 2013).
Non-viral vectors, another kind of vectors that can protect the
nucleic acids from degradation and assist cellular entry, can be
further divided into lipid cations, cationic polyplexes and others
(Guo et al., 2013; Noori-Zadeh et al., 2014; Yin et al., 2014).
Lipid cations, or liposome, incorporate, and compact negatively
charged DNA into nanoparticles. They can be up-taken into
the cytoplasm by endocytosis or membrane fusion. The delivery
efficiency of lipid cations is quite high, but lipid cations may
cause undesirable membrane destabilization and cytotoxicity.
In addition, the unstable batch production makes it hard to
be widely applied (Koirala et al., 2013). Cationic polymers,
including polyethyleneimine (PEI), poly-L-lysine (PLL), are
polymers with cationic groups with positive charge that can
compact nucleic acids, including primary amine, secondary
amine, tertiary amine, and quaternary amine, etc. Because of
the flexibility of chemical structure, cationic polymers-based
polyplexes have many possibilities to deliver nucleic acids and
cause less cytotoxicity (Noori-Zadeh et al., 2014). However,
limited transfection efficiency and the relatively low ability to
bind to nucleic acids impeded its clinical application (Xun
et al., 2014). Others, like chitosan, modified cyclodextrins (CDs),
PLGA, nanobubbles, cell penetration enhancer peptides (Hsu and
Mitragotri, 2011; Cavalli et al., 2013; Favaro et al., 2014; Lai, 2014)
can complex nucleic acids and form nanoparticles and transfect a
wide range of cell types. However, for these carriers, the issues of
efficient loading and the optimal duration of therapeutic effects
need to be carefully addressed.
Physical delivery carriers depend on physical methods to
deliver nucleic acids into cells, such as electroporation, gene
gun, ultrasound, hydrodynamics high pressure injection and
microneedles (Somiari et al., 2000; Newman et al., 2001;
McCaffrey et al., 2016). The delivery process is simple, but the
nucleic acids can be degraded by nucleases easily, so in general
the nucleic acids need to be chemically modified to improve its
stability and biological activity.
THE ADVANTAGES OF MICRONEEDLES
FOR GENE THERAPY
Four major physical methods have been developed so far for
the transdermal delivery of therapeutics including ultrasound
methods, intradermal injection, gene gun and microneedles
(Figure 1). Microneedles (MNs), as a minimally invasive drug
delivery system, can deliver both low-molecular weight and
high-molecular weight agents, including the nucleic acids into
the systemic circulation by penetrating the stratum corneum
(SC), which is the main barrier for intradermal drug delivery.
Microneedles are shaped with arrays of needles ranging from
25 to 2000µm in height (Donnelly et al., 2010). The needles
have different tip shapes and tip intervals, being attached to
a base support. The dimension of microneedles is within the
micron range, but greater than the size of their cargos, so it
will be easy for macromolecules, even drug-excipient complexes
or nanoparticles to get through the micro-channels in the
microneedles. The application of microneedles is pain-free and
patient-friendly, which greatly improves the patient compliance.
Since it is easy to use, microneedles also have the potential for
self-administration. In addition, the low production cost makes
microneedles a promising drug delivery system with marketing
potential as well (Coulman et al., 2006).
FIGURE 1 | Representative physical methods for transdermal delivery.
(A) Ultrasound methods, (B) Intradermal injection, (C) Gene gun, (D)
Microneedles.
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The fabrication of microneedles usually involves many
materials, including stainless steel, ceramics, dextrin, polymers
and glass (Frazier, 2003; Ito et al., 2006; Ovsianikov et al.,
2007; Jiang et al., 2009). Moreover, different fabrication
methods have been used to construct microneedles, including
chemical isotropic etching method, micro-molding method,
the surface/ultrafine processing method, lithography—
electroforming—replication method. Laser-etching prepared
microneedles have also been reported Trichur et al., 2002; Moon
and Lee, 2005). Based on their properties, microneedles
can be divided into several types: solid microneedles,
holliow microneedles, dissolving microneedles, and hydrogel
microneedles (Liu et al., 2014).
Now microneedles have been used for the transdermal
delivery of a broad range of drugs, such as small molecular
weight drugs, oligonucleotides, DNA, peptides, proteins, and
inactivated viruses. Moreover, extensive experiments with
influenza, Calmette–Guérin (BCG), and other vaccines have
shown that vaccine delivery into the skin is also promising
(Gonzalez-Gonzalez et al., 2009; Haq et al., 2009; Kim Y. C.
et al., 2012a; van der Maaden et al., 2012). Recently, microneedles
combined with siRNA have been applied as gene therapy. As
reported, it can efficiently and reproducibly deliver nucleic acids
to the skin for the treatment of genetic skin disorders, cancers,
wounds, and hyper proliferative diseases (McLean and Moore,
2011).
THE SOLID MICRONEEDLES
The solid microneedles are usually made of metals and silicon
using dry or wet etching process. By using potassium hydroxide
(KOH) solution, the part of silicon needles that are not covered
by chromium model can be etched into required shape (Lin and
Pisano, 1999). The solid microneedles usually need a two-step
application. First, it penetrates the SC to form some transient
microchannels. Then the drug solution, or gel, cream, ointment
is applied as a form of a patch on the area of skin. Guang
Yan et al. (Birchall et al., 2005) developed a motorized metal-
based microneedle device for transdermal delivery of plasmid
DNA that encoding enhanced green fluorescent protein and
firefly luciferase (pEGFP-Luc). The authors found that high
gene expression can be obtained and the skin would have
minimal damage with the device. In their study, the authors also
compared the different methods for the delivery of DNA into the
skin, including passive diffusion method, intradermal injection
method andmotorizedmicroneedle devicemethod for delivering
DNA solution. Motorized microneedle device turned out to be
more advantageous than the other two methods in equivalent
conditions. And the result showed that pretreatment of skin
with microneedles followed by application of DNA solution is
less effective than the application of DNA solution at first. The
gene expression of latter method is 87 times higher than the
former one. In addition, Kumar et al. (2012) used Dermaroller R©
microneedle roller, which is also a kind of solid microneedles
made into roller to pretreat the mice skin. Then the plasmid
DNA coated on the surface of cationic PLGA nanoparticles are
applied onto the microneedle-treated area. The results showed
that microneedle-mediated transcutaneous immunization with
plasmid DNA carried by the nanoparticles induced a stronger
immune response than with the plasmid DNA alone. So the solid
microneedles, used as a pretreatment to deliver nucleic acids
subcutaneously appears to be promising.
THE COATED SOLID MICRONEEDLES
The coated solid microneedles avoid a two-step application,
which uses a dip-coating method to coat the proteins, DNA,
viruses or microparticles onto the surface of the needles. The
material used to fabricate the microneedles can be metal, silicon
or even polymer materials. Pearton et al. (2012) fabricated the
steel microneedles into 75 µm thick using an infrared laser.
An optimized dip-coating process was used to coat the pDNA
onto the MNs, of which the loading capacity is up to 100 µg
of pDNA per 5-microneedle array. They believed that suitable
DNA loading, efficient and reproducible skin puncture and rapid
in vivo dissolution of pDNA at the treated site determine the
efficiency of gene expression from coated microneedles. Chong
et al. (2013) used wire electrical discharge machining (EDM) to
fabricate the stainless steel microneedle devices which contained
either 5 or 10 needles of 700 µm length and 200 µm base
width. A coating reservoir was used to load BLOCK-iTTM Alexa
647 fluorescent siRNA into a pipette tip and microneedles. The
theoretical loading onto each microneedle device was 35 µg
siRNA. The fluorescence image showed that the coating of 0.1
µg fluorescent siRNA on the surface of a single steel microneedle
was removed from the surface after a 10 min insertion, which
verified the distribution of siRNA. For in vivo studies, the
microneedles were coated with self-delivery siRNA targeting
the reporter genes (luciferase/GFP). The intravital imaging of
reporter gene expression and the quantification of reporter
mRNA confirmed the functionality of gene silencing following
microneedle delivery. The results demonstrated that coated solid
MNs have the potential to deliver nucleic acids in vivo. The
further study should focus on the delivery of larger doses of
therapeutic siRNAs.
THE DISSOLVING MICRONEEDLES
Dissolving microneedles are always made of biodegradable
polymers, which can dissolve or degrade within the skin. As a
result, there is no need to remove the MNs from patients’ skin.
Compared with coated microneedles, dissolving microneedles
have bigger loading capacity. The drugs loaded into the needles
can quickly release after the insertion into the skin (Donnelly,
2011). Lee et al. (2011) used a hybrid electro-microneedle (HEM)
to achieve a safe and high-capacity gene transfer. The monolithic
fabrication process of the HEM is shown in Figure 2. The HEM
is a monolithic hybrid assembly of a dissolving microneedle
and an electrode. The electrode was used as a drawing pillar to
elongate dissolving microneedles from 2D glassy maltose. The
needles are separated by antidromic isolation in the melting
process. The dissolving microneedles have an ultra-sharp tip
diameter of 5 µm and a length of 400 µm. The cutaneous
permeation and release tests showed that the microneedles of
the HEM dissolved completely in 20 min after insertion into
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FIGURE 2 | The monolithic fabrication of a HEM by drawing lithography
with antidromic isolation. (A) Liquid maltose was coated on a planar
surface, and contacted with the 5 × 5 array electrodes of the HEMs as a
drawing pillar. (B) The glassy maltose between Tm and Tg was elongated by
drawing of electrodes. (C) After lowering the temperature to sub-Tg, the
elongated 3D structures were cured to a solid state. (D) The coating surface
was melted at a temperature greater than Tm to isolate elongated 3D
structures from 2D coating surface, and this antidromic isolation fabricated
dissolving microneedles of the HEMs. Adapted with permission from (Lee
et al., 2011).
the skin. Then the electrode applied electric pulse to facilitate
intracellular transfection of nucleic acids into cells at the release
site. Compared with the negative controls (pCMV-GLuc with
dissolving microneedles alone and the control PCI plasmid with
HEM), the bioluminescence intensity achieved by pCMV-GLuc
transfer with the HEM was significantly higher after 8 to 15
days. The regression of subcutaneous B16F10 by cutaneous
p2CMVmIL-12 transfer using a HEM also lead to a longer
survival time of 45 days for the tested mice.
Gonzalez-Gonzalez et al. (2010) applied a PAD (Protrusion
Array Device) loaded with a fluorescently tagged siRNA mimic
(siGLO Red) onto the mice footpad. They fabricated the
dissolving microneedles under a controlled airflow. A pin
template contacting with a thin film of PVA solution was
withdrawn to form a fiber-like structure, which then was
trimmed to a uniform height with sharp tips. The distribution
and silencing of CBL/hMGFP reporter gene demonstrated that
endogenously expressing genes can be reduced 25–50% by Accell
siRNAs delivered by PADs. And they proposed a combinatorial
approach of PAD and Accell may result in greater efficiency to
knock down the target gene.
Lara et al. (2012) also used the PAD to load CD44 sd-
siRNA both in vitro and in vivo. The treatment with CD44
sd-siRNA decreased CD44 mRNA levels, resulting in a reduction
of the target protein as confirmed by immunodetection.
The results demonstrated that administration of dissolvable
microneedle arrays, loaded with sd-siRNA can reduce expression
of a targeted endogenous gene in a human skin xenograft
model. Based on these favorable results, the dissolving
microneedles could be a good alternative to deliver genetic
materials. A graphic illustration of the mechanisms of
different microneedles for therapeutics delivery is shown
in Figure 3.
FIGURE 3 | The mechanisms of different microneedles to deliver drugs.
(A) The solid microneedles. (B) The coated microneedles. (C) The dissolving
microneedles.
THE EXISTING PROBLEMS OF MNs TO BE
USED FOR GENE THERAPY
Although the microneedles have been verified as an effective and
potentially useful way to deliver siRNA or other nucleic acids into
the skin, many problems still remained to be addressed.
The motorized solid microneedle device utilized by Birchall
et al. (2005) may have the concerns of costly fabrication and
the two-step application still increases the inconvenience of
self-administration. In addition, the treated skin needed to
be punctured for sufficient long duration to get the high
gene expression in the skin. During the application, the
motorized microneedle device could cause some undesirable
damage to the skin, though the study claims to only cause
the minimal damage. Moreover, the breakdown of microneedles
in the skin may be another potential safety problem for solid
microneedles.
The coating of coated microneedles could be restricted to
the tips of microneedles. Devices used to enhance the depth
of skin penetration may also be a potential issue (Coulman
et al., 2011). The coating formulations and procedures may
limit the penetration of skin and efficient drug deposition
at the targeted site, since the viscosity and surface tension
of the formulation could affect the uniform coating of the
microneedles (Chong et al., 2013). In addition, the coating
capacity could be another problem. Pearton et al. (2012) reported
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the fabrication of the coated microneedles with high dose-
loading of pDNA (up to 100 µg of pDNA per 5-microneedle
array). However, compared with other kinds of microneedles,
the loading capacity of the coated microneedles still needs to be
improved.
The dissolving microneedles is composed of biodegradable
polymers, which has the potential issue of biocompatibility
in vivo. Since the dissolving microneedles almost dissolve
completely after the insertion into the skin, we should
pay attention to the safety and biocompatibility of these
dissolving materials and their degradation products. Moreover,
the release kinetics of the dissolving microneedles depends on
the internal structure of the polymer material, which could
be an obstacle for the delivery into the skin. In addition,
some microneedle fabrication procedures involve high polymer-
melting temperatures, some are even above 135◦C, which will
be damaging to some temperature-sensitive drugs, such as
proteins and nucleic acids. Another issue is that the loading
amount of drugs may also affect the needle mechanical properties
when the main matrix is PLGA or carboxymethyl cellulose.
For example, Kim M. et al. (2012b) found that microneedles
with 10% drug loading could not keep the mechanical strength
to penetrate the skin. In addition, for therapeutic nucleic
acids, the intracellular barriers including endosome escape,
releasing from carriers, and entering into nucleus could be
additional challenges. Combining MNs and nanoparticle-based
formulations could be a potentially useful approach to overcome
these intracellular barriers (Kumar et al., 2012; McCaffrey et al.,
2016).
Because of the properties of MNs, the application site is
limited to some certain area on the body, such as arms, hands,
abdomen where the epidermis and SC are easier for MNs to
penetrate. As reported, the dissolving microneedles dissolved
completely in 20 min (Lee et al., 2011), so the duration time for
the application is also critical.
No matter solid microneedles, coated microneedles,
dissolving microneedles, or hollow microneedles, the MNs
are used as a physical delivery method. For gene therapy, the
cargo nucleic acids also need to be improved. MNs facilitating
the delivery of genetic material alone may not be better
than intradermal injection, but the combination of MNs and
electroporation proved to be more effective than injection
alone, which gives us a thought of the combined use of different
delivery techniques. While the other physical delivery carriers
have some shortages such as damages to the skin, the costly
fabrication and patient-unfriendly etc., MNs behaves well at
those aspects, and the electrically controlled pulse may further
improve its efficiency. And some bioactive components can
also be added into the formulation of dissolving microneedles
to enhance its effects. Moreover, the advantage of pain-free
application makes microneedles to act as an optimal strategy
for DNA vaccination. MNs could relieve the patients from the
suffering of multiple injections from days to weeks to develop
immunization.
In conclusion, the further development of microneedles for
gene therapy depends not only on the improved fabrication of
MNs, such as the structures, the mechanical properties and the
formulations etc., but also on the combined use of different
delivery techniques to achieve optimal therapeutic outcomes.
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